Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study

BACKGROUND: Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety and efficacy in patients with coronavirus disease 2019 (COVID-19), and these studies demonstrate conflicting resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Aljuhani, Ohoud, Al Sulaiman, Khalid, Alshabasy, Adel, Eljaaly, Khalid, Al Shaya, Abdulrahman I., Noureldeen, Haytham, Aboudeif, Mohammed, Al Dosari, Bodoor, Alkhalaf, Amina, Korayem, Ghazwa B., Aleissa, Muneera M., Badreldin, Hisham A., Al Harbi, Shmeylan, Alhammad, Abdullah, Vishwakarma, Ramesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559694/
https://www.ncbi.nlm.nih.gov/pubmed/34724920
http://dx.doi.org/10.1186/s12879-021-06813-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559694/
https://www.ncbi.nlm.nih.gov/pubmed/34724920
http://dx.doi.org/10.1186/s12879-021-06813-1

Ejemplares similares